Document ID: FDA-2010-N-0597-0001
Agency: fda
Document Type: Notice
Title: Agency Information Collection Activities; Proposals, Submissions, and Approvals: Index of Legally Marketed Unapproved New Animal Drugs for Minor Species
Posted Date: 2010-12-03T05:00Z

[Federal Register Volume 75, Number 232 (Friday, December 3, 2010)]
[Notices]
[Pages 75481-75482]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-30335]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0597]

Agency Information Collection Activities; Proposed Collection; 
Comment Request; Index of Legally Marketed Unapproved New Animal Drugs 
for Minor Species

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
opportunity for public comment on the proposed collection of certain 
information by the Agency. Under the Paperwork Reduction Act of 1995 
(the PRA), Federal Agencies are required to publish notice in the 
Federal Register concerning each proposed collection of information, 
including each proposed extension of an existing collection of 
information, and to allow 60 days for public comment in response to the 
notice. This notice solicits comments on the burden hours associated 
with indexing of legally marketed unapproved new animal drugs for minor 
species.

DATES: Submit either electronic or written comments on the collection 
of information by February 1, 2011.

ADDRESSES: Submit electronic comments on the collection of information 
to http://www.regulations.gov. Submit written comments on the 
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, 
Rockville, MD 20852. All comments should be identified with the docket 
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Johnny Vilela, Office of Information 
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, 
Rockville, MD 20850, 301-796-7651, juanmanuel.vilela@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal 
Agencies must obtain approval from the Office of Management and Budget 
(OMB) for each collection of information they conduct or sponsor. 
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
1320.3(c) and includes Agency requests or requirements that members of 
the public submit reports, keep records, or provide information to a 
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) 
requires Federal Agencies to provide a 60-day notice in the Federal 
Register concerning each proposed collection of information, including 
each proposed extension of an existing collection of information, 
before submitting the collection to OMB for approval. To comply with 
this requirement, FDA is publishing notice of the proposed collection 
of information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

Index of Legally Marketed Unapproved New Animal Drugs for Minor 
Species--21 CFR Part 516 (OMB Control Number 0910-0620)--Extension

    The Minor Use and Minor Species Animal Health Act of 2004 (MUMS 
Act) amended the Federal Food, Drug, and Cosmetic Act (the FD&C Act) to 
authorize FDA to establish new regulatory procedures intended to make 
more medications legally available to veterinarians and animal owners 
for the treatment of minor animal species (species other than cattle, 
horses, swine, chickens, turkeys, dogs, and cats), as well as uncommon 
diseases in major animal species.
    The MUMS Act added three new sections to the FD&C Act (sections 
571, 572, and 573 (21 U.S.C. 360ccc, 360ccc-1, and 360ccc-2, 
respectively)). The final rule (72 FR 69108, December 6, 2007) 
implements section 572 of the FD&C Act, which provides for an index of 
legally marketed unapproved new animal drugs for minor species. 
Participation in any part of the MUMS program is optional so the 
associated paperwork only applies to those who choose to participate. 
The final rule specifies, among other things, the criteria and 
procedures for requesting eligibility for indexing and for requesting 
addition to the index as well as the annual reporting requirements for 
index holders.
    Under the new subpart C of part 516 (21 CFR part 516, subpart C), 
Sec.  516.119 provides requirements for naming a permanent-resident 
U.S. agent by foreign drug companies, and Sec.  516.121 provides for 
informational meetings with FDA. Section 516.123 provides requirements 
for requesting informal conferences regarding agency administrative 
actions and Sec.  516.125 provides for investigational use of new 
animal drugs intended for indexing. Provisions for requesting a 
determination of eligibility for indexing can be found under Sec.  
516.129 and provisions for subsequent requests for addition to the 
index can be found under Sec.  516.145. A description of the

[[Page 75482]]

written report required in Sec.  516.145 can be found under Sec.  
516.143. Under Sec.  516.141 are provisions for drug companies to 
nominate a qualified expert panel as well as the panel's recordkeeping 
requirements. This section also calls for the submission of a written 
conflict of interest statement to FDA by each proposed panel member. 
Index holders are able to modify their index listing under Sec.  
516.161 or change drug ownership under Sec.  516.163. Requirements for 
records and reports are under Sec.  516.165.
    Description of Respondents: Pharmaceutical companies that sponsor 
new animal drugs.
    FDA estimates the burden of this collection of information as 
follows:

                                 Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
                                                      Annual
         21 CFR Section              Number of    frequency  per   Total annual      Hours per      Total hours
                                    respondents      response        responses       response
----------------------------------------------------------------------------------------------------------------
516.119.........................               2               1               2               1               2
516.121.........................              30               2              60               4             240
516.123.........................               3               1               3               8              24
516.125.........................               2               3               6              20             120
516.129.........................              30               2              60              20           1,200
516.141.........................              20               1              20              16             320
516.143.........................              20               1              20             120           2,400
516.145.........................              20               1              20              20             400
516.161.........................               1               1               1               4               4
516.163.........................               1               1               1               2               2
516.165.........................              10               2              20               8             160
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............           4,872
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

                               Table 2--Estimated Annual Recordkeeping Burden \1\
----------------------------------------------------------------------------------------------------------------
                                                      Annual
         21 CFR Section              Number of     frequency per   Total annual      Hours per      Total hours
                                   recordkeepers   recordkeeper       records      recordkeeper
----------------------------------------------------------------------------------------------------------------
516.141.........................              30               2              60             0.5              30
516.165.........................              10               2              20               1              20
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............              50
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

    Dated: November 29, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-30335 Filed 12-2-10; 8:45 am]
BILLING CODE 4160-01-P